Phenylephrine Versus Eyelid Taping for Muller's Muscle-Conjunctival Resection (MMCR) Evaluation
Ptosis, Eyelid
About this trial
This is an interventional treatment trial for Ptosis, Eyelid
Eligibility Criteria
Inclusion Criteria: Individuals diagnosed with ptosis undergoing conjunctival Muller's muscle resection evaluation. Individuals who can tolerate and have no hypersensitivity to phenylephrine 2.5% ophthalmic solution. Individuals who can tolerate eye-drop medications. Individuals who are physically able to take a tangent screen visual field test. Age: Adults who can comprehend the instructions and procedures (18-90 years old). Exclusion Criteria: - This study will not incorporate any of the following at-risk populations: adults unable to consent, individuals who are not yet adults, pregnant women, prisoners. This study will not include participants who refuse to consent. This study will not include participants who are too tired or unable to take a tangent screen visual field test (see Risk to Subjects). This study will not include individuals who may not be able to tolerate phenylephrine 2.5% ophthalmic solution. Specifically, those with a past medical history of bradycardia, hypotension, autonomic dysfunction, or severe cardiovascular disease This study will not include individuals who consume drugs contraindicated in phenylephrine use: Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates), Iobenguane Radiopharmaceutical Products, Kratom, Lisuride, Monoamine Oxidase Inhibitors
Sites / Locations
- University of Miami Bascom Palmer Eye Institute
Arms of the Study
Arm 1
Experimental
Phenylephrine and Eye Taping Group
Participants in this group will initially have superior visual field testing done with the upper eyelid manually taped. Then, participants will have superior visual field testing done after receiving Phenylephrine 2.5% ophthalmic solution. Participants will be in each group for up to 60 minutes.